EPO906 Therapy in Patients With Advanced Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

August 31, 2003

Conditions
Kidney Neoplasms
Interventions
DRUG

epothilone b

EPO906 administered intravenously at 2.5 mg/m2 as a 5 minute bolus infusion repeated every week for three weeks followed by one week off The final tables and data is not in yet, so I cannot give you info on safety issues.

Trial Locations (8)

10466

Our Lady Of Mercy Medical Center, The Bronx

21201

University of Maryland, Baltimore

44195

Cleveland Clinic Foundation, Cleveland

48201

Wayne State University Karmanos Cancer Center, Detroit

90095

UCLA Medical Center, Los Angeles

98109

University of Washington, Seattle

Unknown

Centre L. Berard, Lyon

Institut Gustave Roussy, Villejuif

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY